Though the former president has repeatedly hyped the impact of his experimental drug program, there’s no basis for his claims in government data, and medical experts say he’s exaggerating.
Category: Clinical Trials
Patients Divided Over Alzheimer’s Drug: Is It a ‘Risk I’m Willing to Take’ or Just a ‘Magic Pill’?
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
- 1
- 2